Randomised phase II trial of olaparib, chemotherapy or olaparib and cediranib in patients with platinum-resistant ovarian cancer (OCTOVA): a study protocol

Anita Mansouri, Naomi McGregor, Rachel Dunn, Sam Dobbie, Jane Holmes, Linda Collins, Shibani Nicum, Anita Mansouri, Naomi McGregor, Rachel Dunn, Sam Dobbie, Jane Holmes, Linda Collins, Shibani Nicum

Abstract

Introduction: Patients relapsing within 12 months of platinum-based chemotherapy usually have a poorer response to subsequent treatments. To date, extensive research into the mechanism of resistance to platinum agents in the treatment of ovarian cancer has not resulted in improved responses or longer survival. Further experimental work and clinical trials with novel agents are therefore justified to address this unmet need.Patients with ovarian, fallopian tube or primary peritoneal cancer that has relapsed within 12 months of platinum-based chemotherapy will be randomised with stratification for BReast CAncer gene (BRCA) status, prior poly (ADP-ribose) polymerase (PARP) exposure and prior antiangiogenic therapy into weekly paclitaxel (chemotherapy), olaparib or the combination of cediranib and olaparib. They will be followed until disease progression or unacceptable toxicity develops. Our trial design permits two investigations. We will compare the efficacy and tolerability of single-agent olaparib with weekly paclitaxel. We will also compare the efficacy and tolerability of olaparib with the combination of olaparib and cediranib. The required sample size of 138 participants (46 per arm) was calculated using a 20% one-sided type I error, 80% power and 15% dropout rate. Recruitment will last 34 months with a follow-up of 18 months.

Methods and analysis: ETHICS AND DISSEMINATION: This study will be conducted under a UK Medicines and Healthcare Products Regulatory Agency Clinical Trials Authorisation. Approval to conduct the study was obtained from the responsible authority before beginning the study. The sponsor will retain ownership of all data arising from the trial. We aim to publish this research in a specialist peer-reviewed scientific journal on study completion. EudraCT number: 2016-000559-28, ethics reference number: 16/LO/2150.

Trial registration number: ISRCTN: ISRCTN14784018, clinicaltrials.gov: NCT03117933; Pre-results.

Keywords: chemotherapy; clinical trials; oncology; toxicity.

Conflict of interest statement

Competing interests: None declared.

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

References

    1. Bray F, Ferlay J, Soerjomataram I, et al. . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394–424. 10.3322/caac.21492
    1. UK CR Ovarian cancer incidence. Available:
    1. Banerjee S, Kaye SB. New strategies in the treatment of ovarian cancer: current clinical perspectives and future potential. Clin Cancer Res 2013;19:961–8. 10.1158/1078-0432.CCR-12-2243
    1. Markman M, Markman J, Webster K, et al. . Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: implications for patient management and clinical trial design. J Clin Oncol 2004;22:3120–5. 10.1200/JCO.2004.05.195
    1. Bryant HE, Schultz N, Thomas HD, et al. . Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005;434:913–7. 10.1038/nature03443
    1. Farmer H, McCabe N, Lord CJ, et al. . Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005;434:917–21. 10.1038/nature03445
    1. Fong PC, Boss DS, Yap TA, et al. . Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers. N Engl J Med Overseas Ed 2009;361:123–34. 10.1056/NEJMoa0900212
    1. Moore K, Colombo N, Scambia G, et al. . Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med Overseas Ed 2018;379:2495–505. 10.1056/NEJMoa1810858
    1. Audeh MW, Carmichael J, Penson RT, et al. . Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. The Lancet 2010;376:245–51. 10.1016/S0140-6736(10)60893-8
    1. Kaye SB, Lubinski J, Matulonis U, et al. . Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer. J Clin Oncol 2012;30:372–9. 10.1200/JCO.2011.36.9215
    1. Ledermann J, Harter P, Gourley C, et al. . Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol 2014;15:852–61. 10.1016/S1470-2045(14)70228-1
    1. Ledermann JA, Embleton AC, Raja F, Erratum: RF, et al. . Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2016;387:1066-1074. 10.1016/S0140-6736(15)01167-8
    1. Liu JF, Barry WT, Birrer M, et al. . Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer. Ann Oncol 2019;30:551–7. 10.1093/annonc/mdz018
    1. Mirza MR, Åvall Lundqvist E, Birrer MJ, et al. . Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial. Lancet Oncol 2019;20:1409–19. 10.1016/S1470-2045(19)30515-7
    1. Perren TJ, Swart AM, Pfisterer J, et al. . A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 2011;365:2484–96. 10.1056/NEJMoa1103799
    1. Kaplan AR, Gueble SE, Liu Y, et al. . Cediranib suppresses homology-directed DNA repair through down-regulation of BRCA1/2 and Rad51. Sci Transl Med 2019;11:eaav4508. 10.1126/scitranslmed.aav4508
    1. Belotti D, Vergani V, Drudis T, et al. . The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin Cancer Res 1996;2:1843–9.
    1. Kamat AA, Kim TJ, Landen CN, et al. . Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer. Cancer Res 2007;67:281–8. 10.1158/0008-5472.CAN-06-3282
    1. Lau D, Guo L, Gandara D, et al. . Is inhibition of cancer angiogenesis and growth by paclitaxel schedule dependent? Anticancer Drugs 2004;15:871–5. 10.1097/00001813-200410000-00007
    1. Lau DH, Xue L, Young LJ, et al. . Paclitaxel (Taxol): an inhibitor of angiogenesis in a highly vascularized transgenic breast cancer. Cancer Biother Radiopharm 1999;14:31–6. 10.1089/cbr.1999.14.31
    1. Milross CG, Mason KA, Hunter NR, et al. . Relationship of mitotic arrest and apoptosis to antitumor effect of paclitaxel. J Natl Cancer Inst 1996;88:1308–14. 10.1093/jnci/88.18.1308
    1. Tan DSP, Yap TA, Hutka M, et al. . Implications of BRCA1 and BRCA2 mutations for the efficacy of paclitaxel monotherapy in advanced ovarian cancer. Eur J Cancer 2013;49:1246–53. 10.1016/j.ejca.2012.11.016
    1. McNeish IA, Ledermann JA, Webber L, et al. . A randomised, placebo-controlled trial of weekly paclitaxel and saracatinib (AZD0530) in platinum-resistant ovarian, fallopian tube or primary peritoneal cancer†. Ann Oncol 2014;25:1988–95. 10.1093/annonc/mdu363
    1. Latimer NR, Abrams KR, Lambert PC, et al. . Adjusting for treatment switching in randomised controlled trials–a simulation study and a simplified two-stage method. Stat Methods Med Res 2017;26:724–51. 10.1177/0962280214557578

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir